Drug intelligence / Profile preview

ANT-301

Development stage: Phase 1
Lead developer: Anterogen
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

ANT-301 is an allogeneic adipose-derived mesenchymal stem cell (AdMSC) therapy developed by Anterogen Co., Ltd. for the treatment of knee osteoarthritis. The product consists of stem cells harvested from healthy donor adipose tissue, which are then expanded and processed for therapeutic use. ANT-301 is designed for intra-articular injection into the knee joint, specifically targeting patients with Kellgren-Lawrence (K&L) Grade III or IV osteoarthritis. The therapy aims to leverage the immunomodulatory and regenerative properties of mesenchymal stem cells to reduce synovial inflammation, alleviate joint pain, and potentially facilitate the repair of damaged articular cartilage, thereby slowing the progression of the disease.

Other names: allogeneic adipose-derived mesenchymal stem cellsAnterogen ANT-301

Beyond the preview

Go deeper on ANT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT-301.

Explore the full profile